Access to innovative anticancer medicines in China: a national survey on availability, price and affordability

Conclusions
The overall accessibility of 33 nationally negotiated innovative anticancer medicines improved from 2020 to 2022. However, the overall availability of most anticancer medicines in China remained at a low level (less than 50%). Further efforts should be made to sufficiently and equally benefit patients with cancer.

Source: BMJ Open - April 25, 2024 Category: General Medicine Authors: Li, W., Lu, W., Chen, H., Zhang, C., Wang, M., Zheng, F., Wu, H.-H., Wan, G.-W., Yang, Q., Ye, L. Tags: Open access, Health services research Source Type: research